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ARTICLE INFO  ABSTRACT 
Glaucoma is the second foremost cause of impaired vision. People who 
suffered from Glaucoma face the independent expenditure for the 
treatment as blind people with Glaucoma could not be cured perfectly. This 
study intends to analyze the effect of age, types of patient care, types of 
Glaucoma, and types of payment on the total cost of care of glaucoma 
patients at Cicendo Eye Hospital, Bandung, Indonesia. This study uses 
3,358 patient medical records of Cicendo Eye Hospital, Bandung, 
Indonesia, in 2018. The 3,358 samples were selected from the patient’s 
medical record based on patients’ categories indicated or convicted of 
having Glaucoma. Robust Linear Regression is applied in this study to 
measure the additional cost for Glaucoma treatment. The results showed 
that the total cost of patient care was positively and significantly affected 
by hospitalization status (p=0.000), age (p=0.000), times of treatment 
(p=0.000), having primary glaucoma (p=0.000), having congenital 
glaucoma (p=0.000), and presence of intraocular (p=0.000). Conversely, 
patient care’s total cost was negatively and significantly affected using 
insurance (p=0.082). This result would be a precautionary measure for the 
medical institution to consider better financial planning, service delivery 
improvement, and the patient’s payment scheme effectiveness. 
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Glaukoma adalah penyebab kedua terbesar dari kebutaan. Orang yang 
menderita glaukoma akan menghadapi pengeluaran yang cukup besar 
untuk perawatan karena orang yang mengalami kebutaan dengan indikasi 
glaukoma tidak dapat disembuhkan dengan sempurna. Tujuan dari 
penelitian adalah untuk menganalisis pengaruh usia, jenis perawatan 
pasien, jenis glaukoma dan jenis pembayaran terhadap total biaya 
perawatan pasien glaukoma di Rumah Sakit Mata Cicendo, Bandung, 
Indonesia. Penelitian ini menggunakan 3.358 rekam medis pasien Rumah 
Sakit Mata Cicendo, Bandung, Indonesia di tahun 2018. 3.358 sampel dipilih 
dari catatan rekam medis pasien berdasarkan kategori pasien yang 
terindikasi atau yang sudah dinyatakan memiliki penyakit Glaukoma. 
Robust Linear Regression diterapkan dalam penelitian ini untuk mengukur 
biaya tambahan untuk perawatan Glaukoma. Hasil penelitian menunjukkan 
bahwa total biaya perawatan pasien dipengaruhi positif dan signifikan oleh 
status rawat inap (p=0,000), usia (p=0,000), waktu perawatan (p=0,000), 
memiliki glaukoma primer (p=0,000), memiliki glaukoma kongenital 
(p=0,000), penanaman lensa buatan (p=0,000). Sebaliknya total biaya 




perawatan pasien dipengaruhi negatif dan signifikan oleh penggunaan 
asuransi (p=0,082). Hasil penelitian ini menjadi pertimbangan dasar bagi 
instansi kesehatan dalam perencanaan keuangan yang lebih baik, 
peningkatan pemberian layanan dan efektivitas skema pembayaran pasien. 
INTRODUCTION 
In the low-middle developing countries 
category, Glaucoma is one of the foremost causes 
of blindness. Approximately 285 million people 
have a visual impairment, and 39 million people 
of them get blind. Glaucoma causes 2% visual 
impairment and 8% permanent blindness. In 
2020, glaucoma patients will increase by 
approximately 76 million worldwide.1 Glaucoma 
is a disease characterized by the damaged optic 
nerve and visual impairment, including 
increased eye pressure that may cause 
blindness.2 Around 60.5 million patients with 
Glaucoma in 2010 forecasted will increase to 
79.6 million in 2020, and 74% of them will have 
Open Angle Glaucoma (OAG).3,4 In Indonesia, 
there are approximately 427.091 inpatients on 
Glaucoma case recorded.5 
Vision loss from Glaucoma has a significant 
negative impact on health quality and create a 
big economic burden.6 The financial obligation 
due to Glaucoma is substantial not only for 
health systems but for the family and the 
patient.7 Mostly rural people, lack of knowledge 
of glaucoma diagnosis has a worse impact on the 
visual condition. Delayed diagnosis and treat-
ment of Glaucoma will create a higher cost to the 
patient. For example, received intraocular lenses 
implant did not have a significant visual 
recovery as the disease diagnosis was too late 
and also created a higher cost.8 Early cost of 
Glaucoma treatment in 5 years studies from 
Mexico have examined the socio-economic 
aspects of glaucoma patients and state that low-
middle income patients would be suffered from 
the cost of Glaucoma treatment rather than high-
income patients.7  
This study aims to analyze factors on the 
total cost of care of glaucoma patients at Cicendo 
Eye Hospital, Bandung, Indonesia, as Cicendo 
Eye Hospital is the leading national eye 
specialization treatment in Indonesia since 
2009. Cicendo Eye Hospital has a broader scale 
for a more diverse patient that could be a 
prominent subject on the research. This study’s 
results and knowledge would be advice or 
consideration for other hospitals and healthcare 
to improve disease treatment quality or even 
guide other research improvements. 
MATERIAL AND METHOD 
The layout of this study was a cross-
sectional study. This study used secondary data 
from patient medical records in the glaucoma 
clinic in Cicendo Eye Hospital, Bandung, 
Indonesia. The population in the glaucoma clinic 
in Cicendo Eye Hospital was 4,269 patients. The 
total sample of this research was 3,358 patient 
medical records. Exact 3,358 record samples 
were used for the study arrange who had a 
glaucoma symptom.  Some patients come to the 
glaucoma polyclinic to check for glaucoma 
status. After being examined, the patient did not 
have glaucoma symptoms. This study did not 





include patients who did not have glaucoma 
symptoms.  
The glaucoma symptom data collected 
based on the ICD-10 Glaucoma Reference Guide, 
and it was categorized for Primary Glaucoma 
and Secondary Glaucoma. ICD-10 code with 
H40.1, H40.2, and Q15.0 was the Primary 
Glaucoma. Diabetes Mellitus non-insulin 
retinopathy (E11.3), Cataract (H25.0, H25.1, 
H25.2, H26.1, H26.2, and H26.4) Injury (H11.3, 
H43.8, S05.0, S05.1, and S05.8), Inflammation 
(H00.0, H01.0, H10.1, H16.0, H16.2, H17.0, and 
H30.8), hypertension and intraocular disease 
(H05.2, H21.0, H33.0, H33.2, H33.4, H34.8, and 
H35.0) were the Secondary Glaucoma. Presence 
of Intraocular lens (Z96.1), other diagnoses 
(H40.0, H04.1, H11.0, H18.1, H27.0, H27.1, 
H35.5, H35.6, H40.8, H53.1, T15.0, H40.5) that 
included in Secondary Glaucoma Caused by 
Other Disease.  
This data would observe total healthcare 
costs in Rupiah (IDR) currency (summed from 
medicine cost, patient treatment cost, the 
patient’s factors and get a natural logarithm for 
the variable as the data transformation choices 
from the ladder in STATA) as the dependent 
variable. The independent variables for this case 
would be the age of the patient, Treatment 
Status (Dummy Variable, 1=Inpatient 
0=Outpatient), Healthcare Utilization (number 
of outpatient visit+inpatient treatment), Pri-
mary Glaucoma and Secondary Glaucoma, 
Presence of Intraocular Lenses (Dummy 
Variable, 1=Yes 0=No), and Government aid 
payment presence (Dummy Variable, 1= Badan 
Penyelenggara Jaminan Sosial (BPJS) user, 
0=Another payment bases). This research used 
statistical analysis with descriptive statistics and 
robust linear regression. The use of robust linear 
regression had been done to avoid the problem 
of classical assumptions.9 All variables were 
considered significant at p<0,05. This research 
has gone through the ethical review process and 
obtained accurate information by the Research 
Ethics Committee of Universitas Padjadjaran 
with No. 788/UN6.KEP/EC/2019.  
RESULTS 
Summary statistics of the sample on this 
project has shown that there were appro-
ximately 3,358 patients with Glaucoma at 
Cicendo Eye Hospital in 2018. The average age of 
patients was 55.55 years (standard deviation 
16.02). This observation’s total cost was 
estimated at Rp2,804,877 in 2018, with the 
minimum total spent on glaucoma treatment, 
including the initial patient registration fee, 
initial examination, and medication costs were 
around Rp 10,000 at minimum and Rp 
71,750,000 at maximum spending. Moreover, 
patients came to the hospital for treatment five 
times on average, and 17.7% had hospitalized 
records.  
The patients categorized with the disease 
by 32.3% of patients had primary Glaucoma 
separated by 12.8% were OAG, and 19.2% were 
ACG. 63.7% of patients have faced secondary 
Glaucoma that happened with the symptoms, 
such as on average, cataract history by 2.89%, 
Ocular pressure by 5.66%, Diabetes mellitus 
with non-insulin therapy for retinopathy by 




0.0685%. Leading causes of Secondary 
Glaucoma that categorized on the observation in 
mean, approximately 0.0715% caused by an 
injury that happens with or without the 
coincidence, 4.68% driven by Inflammation that 
occurred by many diseases, 1.01% of patient 
suffered Glaucoma by drugs, and 4.71% of 
patients suffered from other Glaucoma 
diagnosed. Furthermore, as the relationship 
with Inflammation after cataract/glaucoma 
surgery, patients with Intraocular lenses in 
Cicendo Eye Hospital reach 10.1% on average. 
Last, patients with Congenital Glaucoma reach 
0.83% (Table 1). 
Approximately 1,401 patients were 
recorded to have the main type of Glaucoma 
(Primary or Secondary Glaucoma). Related to 
the history of hospitalization, more patients with 
primary Glaucoma had been hospitalized for 
54.57% of patients than patients with secondary 
Glaucoma, which were only 7.41% hospitalized 
in 2018.  For the age category of patients, the 
average glaucoma patients over the age of 40 
years, where primary Glaucoma dominated by 
more than 50 years old patients, which was 
74.48% and those with secondary Glaucoma 
dominated by more than 50 years old patients, 
which was 60.68% of the total patients with 
secondary Glaucoma (Table 2).  
Interestingly, on average, young patients 
began to detect primary and secondary 
Glaucoma in the age range 11 to 20 years, when 
secondary Glaucoma dominates the age 
category, which was 3.13% of total secondary 
glaucoma patients compared to primary 
Glaucoma that only around 1.24% of total 
primary glaucoma patients. To pay for all health 
examination activities on primary and 
secondary Glaucoma, 99.62% of patients tend to 
pay with another type of payment (cash or 
another insurance), and 0.38% of patients pay 
for the treatment with BPJS/JKS. Furthermore, 
in some cases, glaucoma patients could have 
surgery from a previous diagnosis. One of the 
treatments is post-operative cataract medica-
tion with intraocular lens placement.10 There 
was 7.62% of primary glaucoma patients with 
Intraocular Lens and 8.26% of secondary 
glaucoma patients having Intraocular Lens’ 
appearance (Table 2). 
Table 1. Summary Statistics 
Variable N Mean SD Min Max 
Total cost (Rp) 3,358 2,804,877 5,113,345 10,000 71,750,000 
Total Cost (log) 3,358 13.72 1.564 9.210 18.09 
Inpatient Status  3,358 0.177 0.382 0 1 
Age (years) 3,358 55.55 16.02 0 98 
Times of treatment 3,358 5.355 3.898 1 27 
Primary glaucoma 3,358 0.313 0.464 0 1 
Congenital glaucoma 3,358 0.009 0.094 0 1 
Intraocular lenses 3,358 0.107 0.309 0 1 
Open angle glaucoma  3,358 0.128 0.334 0 1 
Angle closure glaucoma  3,358 0.191 0.394 0 1 
BPJS  3,358 0.005 0.069 0 1 
Secondary Glaucoma 3,358 0.064 0.244 0 1 
Source: Secondery Data Cicendo Eye Hospital’s Medical Record, 2019 
 









n = 1050 % n = 351 % 
Hospitalized Record     
Never been hospitalized 477 45.43 325 92.59 
Ever been hospitalized 573 54.57 26 7.41 
Payment Type     
Other Payment Users 1046 99.62 350 99.72 
BPJS Users 4 0.38 1 0.28 
Age (Years)     
0 – 10 0 0 0 0 
11 – 20 13 1.24 11 3.13 
21 – 30 36 3.43 33 9.40 
31 – 40 58 5.52 32 9.12 
41 – 50 161 15.33 62 17.66 
> 50 782 74.48 213 60.68 
Intraocular Lenses     
No presence of intraocular lens (es) 970 92.38 322 91.74 
Presence of intraocular lens (es) 80 7.62 29 8.26 
Source: Secondery Data Cicendo Eye Hospital’s Medical Record, 2019 
 
Many patients are diagnosed as suspected 
Glaucoma (H40.0) in exceptional cases, and 
some of them might be diagnosed as congenital 
Glaucoma. Characteristics of this category were 
the number of patients diagnosed with 
congenital Glaucoma being hospitalized by 80% 
of them, and 20% did not have hospitalization 
records. For the suspected patient, all of them 
were never hospitalized before. Suspected 
patients around 0.56% only used BPJS Insurance 
as payment, and the rest were paid the 
examination bill with another payment type.  
Moreover, the patients were categorized 
by age that on congenital Glaucoma 53.33% 
mainly from a young age (around 0-10 years old) 
and only one patient that approximately 40 
years old that have congenital Glaucoma, as for 
the suspected glaucoma patients, there was 
66.94% patient that categorize around > 50 
years old, and the rest spread widely. For the 
last, 13.02% of patients were exposed to the 
presence of an intraocular lens implanted in 
their eye, and 100% of congenital glaucoma 
patients did not have an intraocular implant 
(Table 3). 
Robust Model in Linear Regression chosen 
in concern of the parametric and non-parametric 
variables in the data.11 The result concludes that 
the patient’s age has a positive relationship with 
the healthcare cost that every patient that one 
year older than another patient could be 
increasing the glaucoma healthcare cost 
significantly by 0.7% caused by congenital 
Glaucoma. Early-age detection for Glaucoma 
might be hard to do because children (especially 
babies) had smaller eyes than adults. Same with 
age, hospital aspects from the patient such as 
treatment time and hospitalized record have a 
significant relationship with healthcare costs as 
each 1-time patient check to the hospital could 
increase the payment by 17.3% and 202% 
higher if the patient is hospitalized being 
outpatient status, respectively. 
 




The disease has significant involvement in 
the increase in healthcare costs as it is the main 
concern of this study. Primary Glaucoma that 
divides into POAG and PACG has a significant 
increasing effect on the cost. People with earlier 
treatment would be served less cost as each 
treatment for Primary Glaucoma will increase 
the expenditure by 28.4%. The treatment cost on 
Congenital Glaucoma that mainly attacks young 
people would be expensive as each treatment 
will gradually increase the expenditure by 
114.3%. Secondary Glaucoma with no other side 
disease treatment involves increasing expen-
diture by 8.5% and multiplying when combined 
with another symptom. People with Intraocular 
Lenses on their eyes have another cost factor for 
glaucoma treatment.  
Those who have Intraocular Lenses will 
increase the expenditure by 14.2%.  Patients 
that use public health insurance have a 
prosperity chance that Badan Penyelenggara 
Jaminan Sosial (BPJS) has decreased the 
payment by 48.9%. Without any symptoms and 
factors involved, the change in cost will be an 
11.95% raise each year (Table 4). 
Table 3. Special Case Patient Characteristics 
Variable 
Diagnosis of Glaucoma 
Congenital Suspected 
n = 30 % n = 1966 % 
Hospitalized Record     
Never been Hospitalized 6 20.00 1966 100.00 
Ever been Hospitalized 24 80.00 0 0 
Payment Type     
Other Payment Users 30 100.00 1955 99.44 
BPJS Users 0 0 11 0.56 
Age     
0 – 10 16 53.33 4 0.20 
11 – 20 8 26.67 54 2.75 
21 – 30 5 16.67 137 6.97 
31 – 40 0 0 149 7.58 
41 – 50 1 3.33 306 15.56 
> 50 0 0 1316 66.94 
Intraocular Lenses     
No presence of Intraocular 30 100.00 1710 86.98 
Presence of Intraocular 0 0 256 13.02 
 Source: Secondery Data Cicendo Eye Hospital’s Medical Record, 2019 
 
Source: Secondery Data Cicendo Eye Hospital’s Medical Record, 2019 
*p<0.1 | **p<0.01 
  
Table 4. Regression Result 
Log (Cost) Coef. SE t p 95% Conf. Interval 
 Inpatient Record, 1= Inpatient 2.021 0.060 33.83 0.000** 1.904 2.139 
 Patient Age 0.007 0.001 6.14 0.000** 0.005 0.009 
 Times of Treatment  0.173 0.005 37.72 0.000** 0.164 0.182 
 Primary Glaucoma 0.284 0.050 5.65 0.000** 0.185 0.382 
 Secondary Glaucoma 0.085 0.073 1.16 0.248 -0.059 0.229 
 Congenital Glaucoma 1.143 0.242 4.72 0.000** 0.669 1.618 
 Presence of Intraocular 0.142 0.039 3.64 0.000** 0.066 0.219 
 BPJS -0.489 0.282 -1.74 0.082* -1.041 0.063 
 Constant 11.945 0.073 163.83 0.000** 11.802 12.088 
Mean Dependent Var 13.725 SD Dependent Var  1.564 
R-squared  0.669 Number of Obs   3358.000 
F-test   795.925 Prob > F  0.000 
Akaike crit. (AIC) 8836.665 Bayesian Crit. (BIC)  8891.737 






Many aspects can influence the total cost of 
glaucoma care. This model’s interpretation uses 
the log method to present how many factors are 
involved in the healthcare cost with glaucoma 
patients and how much patients will use their 
money when one of their families is diagnosed 
with Glaucoma and its association.  Song et al. 
found that age had a strong correlation with 
Glaucoma, and this study estimated that 3% of 
the global population over 40 years of age 
currently has Glaucoma.6 More glaucoma cases 
for older people will increase the total cost of 
glaucoma care. El-Medany et al. found that the 
number of hospital visits was having a 
significant increase in the total cost of glaucoma 
care,12 and this research in line with our findings 
Lin et al. found that age and hospitalization days 
increase the hospitalization cost significantly. So 
reducing unnecessary inpatient time can control 
the increase of hospitalization cost due to 
glaucoma care.13  
McGinley, et al calculated the total cost of 
glaucoma care without a secondary diagnosis of 
Glaucoma. This research found that the total cost 
falls insignificant. The most recent data from 
2017–2018 found that patients with a recorded 
secondary diagnosis of Glaucoma accounted for 
9% of expenses for falls (£221,681/£2,489,928), 
with a mean cost of £2,806 versus £3,074.5 for 
those with no secondary diagnosis of Glau-
coma.14 This conclusion was in line with our 
finding that secondary Glaucoma gives a positive 
effect but not significant to the total cost of 
glaucoma care.  
Treating a patient that having Congenital 
Glaucoma would have a possibility for taking 
many types of surgery for a long time, and would 
be taking a complex treatment if the disease 
couldn’t be recognize earlier.15 Liu, et al found 
that congenital Glaucoma has a positive and 
significant impact on glaucoma cost. This paper 
found that childhood glaucoma will create a 
significant economic burden on the healthcare 
system and caregivers the highest price created 
by surgical intervention. Liu et al. found the 
direct costs are significant in the first years of the 
disease.16  
Blanco et al. enrolled patients from 30 
hospital eye services in five countries. They 
found the lens extraction was more expensive 
than the standard care. This paper found that the 
incremental cost effectiveness ratio was £14,284 
for initial lens extraction compares to standard 
care.17 Javanbakht et al. reinforce the statement 
that treatment cost for the lens extraction for 
£2467 in United Kingdom rather than standard 
care of glaucoma treatment.18 
Nayak, et al found that 8% of patients had 
their medical costs reimbursed due to Glaucoma 
from health insurance or government schemes.19 
The reimbursed ease the cost of glaucoma 
treatment. This finding also in line with our 
finding that BPJS influences the decreasing total 
cost of glaucoma care at a 10% significance level, 
as the users mostly using another insurance or 
the one that financially stable often paid in direct 
cash for this case. Puspasari, et al in their 
research based on the medical record des-
cription method on Dr. Soedarso Hospital, 




Pontianak, found that the BPJS patients have 
lower payment for typhoid fever patients by 
2.71% rather than direct cash payment for 
typhoid fever patient.20     
The determinant cost for this study has not 
been linked to the hospital’s direct costs for 
glaucoma treatment, such as labor costs, 
equipment costs, land costs, and building costs. 
For future research, two things can be examined, 
and there are the direct costs associated with 
glaucoma treatment at the hospital and the 
indirect costs that the patient must incur, 
namely social costs.  
CONCLUSION AND RECOMMENDATION 
This study analyzes the factors that affect 
the total cost of glaucoma healthcare at Cicendo 
Eye Hospital, Bandung, Indonesia. There are 
some factors that increase the total cost of care 
significantly like hospitalization status (p= 
0.000), age (p=0.000), times of treatment (p= 
0.000), having primary glaucoma (p=0.000), 
having congenital glaucoma (p=0.000), and 
presence of intraocular (p=0.000). One factor 
increases the total cost of care but not 
significant, like having secondary Glaucoma 
(p=0.248). Conversely, patient care’s total cost 
was negatively and significantly affected by 
insurance (p=0.082). Most of the patients use the 
BPJS Insurance as insurance from the 
government. Robust linear regression uses in 
this study examines every aspect that will affect 
the glaucoma treatment expenditure and offers 
a statement that would support patients in 
preliminary diagnosis to prevent high-cost care 
due to complications.  
This result would be a precautionary 
measure for the medical institution to consider 
better financial planning for the service delivery 
improvement and the patient’s payment scheme 
effectiveness. Glaucoma could be a tremendous 
problem in Indonesia if people barely under-
stand primary medical care. The government’s 
consideration for the public health program 
about Glaucoma could sustain people with 
better services and make concrete policies about 
glaucoma health care for welfare.  
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